PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 19.11.2019 at 4:00 PM CET
Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017133657) PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA



Disclaimer The image version (PDF) available on PATENTSCOPE is the official version. This online html version is provided to assist users. Despite the great care taken in its compilation to ensure a precise and accurate representation of the data appearing on the printed document/images, errors and/or omissions cannot be excluded due to the data transmittal, conversion and inherent limitations of the (optional) machine translation processes used. Hyperlinks followed by this symbol , are to external resources that are not controlled by WIPO. WIPO disclaims all liability regarding the above points.

INTERNATIONAL SEARCH REPORT (ISR)
Part 1:  1  2  3  4  5  6          Part 2:  A  B  C  D  E 
International application No. Applicant's or agent's file reference
PCT/CN2017/072814 PF170031PCT
International filing date (day/month/year) (Earliest) Priority Date (day/month/year)
03 February 2017 05 February 2016
Applicant
SAVIRA PHARMACEUTICALS GMBH et al
FOR FURTHER ACTION: See Form PCT/ISA/220 as well as, where applicable, item 5 below.
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.
It is also accompanied by a copy of each prior art document cited in this report.
1. Basis of the report
a. With regard to the language, the international search was carried out on the basis of:
the international application in the language in which it was filed.
a translation of the international application into                                          which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
b.
This international search report has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).
c.
With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing filed or furnished:
2. Certain claims were found unsearchable
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1.
Claims Nos.: 13
because they relate to subject matter not required to be searched by this Authority, namely:
[1] Claim 13 is directed to a method for treatment of the human body by therapy. This search report has been established on the basis of the use of the said compounds for manufacture of medicaments thereof.
2.
Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.
Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
3. Unity of invention is lacking
4. Title of the invention
The text is approved as submitted by the applicant.
The text has been established by this Authority to read as follows:
PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA

5. Abstract
The text is approved as submitted by the applicant.
The text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

Provided herein is a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, enantiomer,or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing influenza.


6. Drawings
a.
The figure of the drawings to be published with the abstract is Figure No. ____________
as suggested by the applicant.
as selected by this Authority, because the applicant failed to suggest a figure.
as selected by this Authority, because this figure better characterizes the invention.
b.
none of the figures is to be published with the abstract.

A. CLASSIFICATION OF SUBJECT MATTER

     C07D 401/14 (2006.01)i; C07D 403/14 (2006.01)i; C07D 413/14 (2006.01)i; C07D 417/14 (2006.01)i; A61K 31/16 (2006.01)i; A61K 31/185 (2006.01)i
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols):
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used):
WPI;EPODOC;CNPAT;CAPLUS(STN);REG(STN);MARPART(STN):pyridin+,pyrimidin+,pyrrol+,influen+

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
(1)
X
WO 2015103453 A1 (BRISTOL-MYERS SQUIBB COMPANY) 09 July 2015 (2015-07-09)
1-10,12
Claim10 and Examples
(2)
X
WO 2014114695 A1 (PALOBIOFARMA S.L) 31 July 2014 (2014-07-31)
1-10,12
Table 2 and Claim 21
(3)
X
WO 2008043019 A1 (PHARMACOPEIA, INC.) 10 April 2008 (2008-04-10)
1-10,12
Paragraphs [00132],[00134], [00137],[00139],[00142],[00144]
(4)
X
WO 2010022358 A1 (LIGAND PHARM. INC.) 25 February 2010 (2010-02-25)
1-10,12
Paragraphs [0184],[0186],[0191],[0192]
(5)
X
WO 2006108103 A1 (PHARMACOPEIA DRUG DISCOVER,INC) 12 October 2006 (2006-10-12)
1-10,12
Paragraphs [00180],[00182]
(6)
X
COLE Andrew G. et al., "2-Benzimidazolyl-9-(chroman-4-yl)-purinone derivatives as JAK3 inhibitors", Bioorganic & Medicinal Chemistry Letters,Vol. 2009, No. 19, 25 September 2009 (2009-09-25),
1-10,12
Pages 6788-6892
(7)
X
SABAT Mark et al., "The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase(Lck)", Bioorganic & Medicinal Chemistry Letters,Vol. 2006, No. 16, 25 September 2006 (2006-09-25),
1-10,12
Pages 5973–5977
(8)
X
WO 2012083117 A1 (VERTEX PHARM. INC.) 21 June 2012 (2012-06-21)
1-13
Claims 1,48-51
(9)
X
WO 2013184985 A1 (VERTEX PHARM. INC.) 12 December 2013 (2013-12-12)
1-13
Claims 1,38-40
(10)
X
WO 2012083122 A1 (VERTEX PHARM. INC.) 21 June 2012 (2012-06-21)
1-13
Claims 1,44-47
(11)
X
WO 2012083121 A1 (VERTEX PHARM. INC.) 21 June 2012 (2012-06-21)
1-13
Claims 1.44-47
*
Special categories of cited documents:
"A"
document defining the general state of the art which is not considered to be of particular relevance
"E"
earlier application or patent but published on or after the international filing date
"L"
document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"
document referring to an oral disclosure, use, exhibition or other means
"P"
document published prior to the international filing date but later than the priority date claimed
"T"
later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"
document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"
document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"
document member of the same patent family

D. INFORMATION ON PATENT FAMILY MEMBERS

Patent document cited in search report Publication date
(day/month/year)
Patent family member(s) Publication date
(day/month/year)
WO 2015103453 A1
09 July 2015
TW 201609693 A
MX 2016008723 A
JP 2017501202 A
CA 2935329 A1
US 2015191464 A1
CN 106061967 A
EP 3089973 A1
UY 35935 A
PH 12016501164 A1
US 9169252 B2
SG 11201605340Q A
KR 20160101191 A
EA 201691343 A1
AU 2015204045 A1
16 March 2016
07 September 2016
12 January 2017
09 July 2015
09 July 2015
26 October 2016
09 November 2016
30 June 2015
15 August 2016
27 October 2015
28 July 2016
24 August 2016
30 November 2016
18 August 2016
WO 2014114695 A1
31 July 2014
EP 2948443 B1
US 9447095 B2
AU 2014209950 A1
SI 2948443 T1
KR 20150126601 A
DK 2948443 T3
ES 2480341 A1
LT 2948443 T
MX 2015009627 A
PL 2948443 T3
US 2015336953 A1
EP 2948443 A1
CN 105008346 A
EA 201591369 A1
SM T201600428 B
CA 2897260 A1
JP 2016505059 A
ES 2480341 B1
31 August 2016
20 September 2016
27 August 2015
30 December 2016
12 November 2015
12 December 2016
25 July 2014
12 December 2016
25 April 2016
28 February 2017
26 November 2015
02 December 2015
28 October 2015
29 January 2016
10 January 2017
31 July 2014
18 February 2016
22 January 2015
WO 2008043019 A1
10 April 2008
US 7915268 B2
TW 200837064 A
US 2008085898 A1
CL 2007002867 A1
AR 063141 A1
29 March 2011
16 September 2008
10 April 2008
27 June 2008
30 December 2008
WO 2010022358 A1
25 February 2010
JP 2012500805 A
WO 2010022358 A8
US 2009069289 A1
EP 2326647 A4
US 7902187 B2
EP 2326647 A1
CA 2735048 A1
12 January 2012
24 March 2011
12 March 2009
26 December 2012
08 March 2011
01 June 2011
25 February 2010
WO 2006108103 A1
12 October 2006
NZ 562468 A
AU 2006232105 A1
MX 2007012393 A
CA 2604161 A1
JP 2008534689 A
IL 186451 D0
US 2007021443 A1
NO 20075560 A
RU 2007140903 A
KR 20080013886 A
BR PI0610514 A2
EP 1874772 A1
30 October 2009
12 October 2006
22 February 2008
12 October 2006
28 August 2008
20 January 2008
25 January 2007
20 December 2007
20 May 2009
13 February 2008
16 November 2016
09 January 2008
WO 2012083117 A1
21 June 2012
KR 20140014110 A
CA 2822057 A1
RU 2013132681 A
CN 103492381 A
MX 2013006836 A
US 8871774 B2
US 2014005192 A1
JP 2013545816 A
AU 2011343642 A1
EP 2651940 A1
05 February 2014
21 June 2012
27 January 2015
01 January 2014
26 September 2013
28 October 2014
02 January 2014
26 December 2013
02 May 2013
23 October 2013
WO 2013184985 A1
12 December 2013
EP 2858984 A1
15 April 2015
WO 2012083122 A1
21 June 2012
KR 20130128435 A
JP 2013545818 A
CA 2822062 A1
RU 2013132683 A
US 2013345218 A1
MX 2013006840 A
WO 2012083122 A8
EP 2651938 A1
CN 103562205 A
AU 2011343647 A1
26 November 2013
26 December 2013
21 June 2012
27 January 2015
26 December 2013
31 January 2014
05 December 2013
23 October 2013
05 February 2014
02 May 2013
WO 2012083121 A1
21 June 2012
AU 2011343646 A1
MX 2013006846 A
CA 2822059 A1
CN 103492382 A
KR 20130128436 A
RU 2013132717 A
US 2014005197 A1
EP 2651941 A1
JP 2013545817 A
02 May 2013
16 December 2013
21 June 2012
01 January 2014
26 November 2013
27 January 2015
02 January 2014
23 October 2013
26 December 2013
Name and mailing address of the ISA/:
STATE INTELLECTUAL PROPERTY OFFICE OF THE P.R.CHINA
6, Xitucheng Rd., Jimen Bridge, Haidian District, Beijing 100088
China
Facsimile No. (86-10)62019451
Date of the actual completion of the international search:
10 April 2017
Date of mailing of the international search report:
26 April 2017
Authorized officer:
AN,Lingling
Telephone No. (86-10)82246746
Top    Part 1: 1 2 3 4 5 6         Part 2: A B C D E